The photo has been used for illustration purposes only.
Gulf Today, journalist
The United Arab Emirates became the second country in the world to approve the registration and use of Biogen’s Aduhelm (aducanumab), the first and only drug for the treatment of early stages of Alzheimer’s disease.
The United Arab Emirates Department of Health and Prevention (MoHAP) announced approval on Sunday after receiving a call from the Food and Drug Administration (FDA) to begin registration and use of the drug Aduhelm from Biogen for Alzheimer’s disease.
This step allows patients with Alzheimer’s disease in the United Arab Emirates and countries in the region to have early access to this innovative drug, which results in the acceleration of their treatment plan and the improvement of their quality of life.
Aduhelm is supplied as injections containing a dose of 100 ml. The drug is prescribed to patients with early stages of Alzheimer’s disease (mild cognitive impairment and mild dementia) by reducing beta-amyloid plaques in the brain.
The drug registration follows the application of MoHAP’s innovative mechanism to its accelerators to assess and approve breakthrough drugs around the world in accordance with the Fast Track / Accelerate Process system. This is coupled with the emphasis on the importance of early diagnosis and the development of medical practices related to Alzheimer’s disease to achieve social and psychological empowerment.
AbdulRahman Bin Mohammed Al Owais, Minister of Health and Prevention, said this milestone is in line with directives from wise leaders to strengthen the UAE’s leadership position in attracting and delivering drugs that have proven to be effective. and efficient to be integrated into treatment. protocols.
Al Owais noted that flexible supply chains and the enactment of legislation that follows developments in the pharmaceutical industry go a long way in accelerating patient recovery and improving their quality of life, which is a top priority for the ministry and other health authorities.
The Minister of Health indicated that the UAE is among the fastest countries in the world in terms of approval of innovative drugs, increasing the chances of recovery for patients in the UAE and the region.
Rachid Azar, Executive Vice President, Alzheimer’s and Cognitive Impairments, said: âBiogen’s tireless research efforts and dedication to achieving its goals have enabled us to fulfill our commitment to provide the first such treatment in many years. many years to patients with Alzheimer’s disease. believe that this drug will give patients with early-stage Alzheimer’s disease, their families and healthcare providers a new ray of hope, especially as they await scientific progress in this regard for decades.
Dr Paul Aisen, Alzheimer’s Therapeutic Research Institute (ATRI), University of Southern California, said: âFor the first time in history, we have achieved an unprecedented feat by going beyond the treatment of symptoms of Alzheimer’s disease to target its main causes. Early detection and diagnosis of MCI will allow us to identify patients who could benefit from this innovative treatment.